Guild Investment Management Inc. Grows Stock Position in Novo Nordisk A/S $NVO

Guild Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 20.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 36,995 shares of the company’s stock after purchasing an additional 6,345 shares during the quarter. Novo Nordisk A/S makes up approximately 2.2% of Guild Investment Management Inc.’s investment portfolio, making the stock its 19th largest position. Guild Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $2,553,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $27,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $30,000. Disciplina Capital Management LLC increased its holdings in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9%

Shares of NVO opened at $59.10 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $120.56. The company has a 50 day simple moving average of $54.84 and a two-hundred day simple moving average of $63.48. The firm has a market cap of $263.90 billion, a P/E ratio of 16.24, a price-to-earnings-growth ratio of 2.66 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Analyst Ratings Changes

Several research firms recently issued reports on NVO. Weiss Ratings reissued a “hold (c-)” rating on shares of Novo Nordisk A/S in a report on Saturday, September 27th. TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 19th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $77.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.